Article
Antitumour activity of an inhibitor of miR-34a in liver cancer with β-catenin-mutations.
Gut - 1 Jun 2016
Gougelet Angélique, Sartor Chiara, Bachelot Laura, Godard Cécile, Marchiol Carmen, Renault Gilles, Tores Frédéric, Nitschke Patrick, Cavard Catherine, Terris Benoit, Perret Christine, Colnot Sabine
Abstract excerpt
OBJECTIVE: Hepatocellular carcinoma (HCC) is the most prevalent primary tumour of the liver. About a third of these tumours presents activating mutations of the β-catenin gene. The molecular pathogenesis of HCC has been elucidated, but mortality remains high, and new therapeutic approaches, including treatments based on microRNAs, are required. We aimed to identify candidate microRNAs, regulated by β-catenin,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.